Retina

Counsel your at-risk patients on strategies to minimize severe hypoglycemia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

The good, the bad, and the questionable.

The first approved GA treatment leaves room for additional therapies.

Drs Paul Chous and Jeffry Gerson brought a new spin on the diabetes talk they've been presenting the last 18 years at the American Academy of Optometry annual meetings.

This podcast provides a review of some of the key highlights from the Controversies in Modern Eye Care meeting held in April 2023. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Steven Ferrucci, OD, FAAO, discusses imaging techniques and treatment options for geographic atrophy as part of his AAOpt presentation alongside Carolyn Majcher, OD, FAAO.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

Prevention should be at the forefront of the discussion.

T1D is one of the most common chronic diseases affecting pediatric populations.

Clinicians may have difficulty in making a diagnosis.

You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

Unpacking the connection between type 2 diabetes and Alzheimer disease.

Opthea’s lead biologic drug candidate OPT-302, which is under investigation for the treatment of wet AMD, received nonproprietary drug name sozinibercept, which is a critical step in the FDA approval process.

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

A single, consistent modality leads to better geographic atrophy tracking.

Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.